{ "ok": true, "cik": "1551152", "ticker": "ABBV", "name": "AbbVie Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-03", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/0001104659-26-104940-index.htm" }, { "form": "8-K", "filed": "2026-08-18", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/0001104659-26-098367-index.htm" }, { "form": "8-K", "filed": "2026-08-05", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926091269/0001104659-26-091269-index.htm" }, { "form": "10-Q", "filed": "2026-08-03", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm" }, { "form": "8-K", "filed": "2026-07-31", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/0001551152-26-000023-index.htm" }, { "form": "8-K", "filed": "2026-07-06", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/0001551152-26-000021-index.htm" } ], "events12m": 15, "healthWatch": { "window": "last 12 months", "since": "2025-09-26", "signals": [], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001551152.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1551152" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up AbbVie Inc. ($ABBV). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-09-03. 15 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 61160000000, "revenueGrowth1y": 0.08566762523520421, "revenueGrowthPerYear": 0.02138290840395274, "yearsOfData": 5, "operatingMargin": 0.24648463047743624, "operatingMarginPrior": 0.16219334682429792, "netMargin": 0.06921190320470896, "operatingCashFlow": 19030000000, "capitalSpending": 1214000000, "freeCashFlow": 17816000000, "researchAndDevelopment": 9096000000, "researchShareOfRevenue": 0.1487246566383257, "cash": 5229000000, "longTermDebt": 64997000000, "longTermDebtChange": -0.03197605147146432, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 56197000000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 58054000000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 54318000000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 56334000000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 61160000000 } ], "totalEquity": -3270000000, "totalAssets": 133960000000, "equityRatio": -0.02441027172290236, "returnOnEquity": null, "dividendsPaid": 11657000000, "payoutRatio": 2.753838884951571, "dividendPerShare": 6.65, "dividendYearsRising": 11, "dividendCut": false, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": 2.37, "sharesOutstanding": 1773000000, "bookValuePerShare": -1.844331641285956, "revenuePerShare": 34.49520586576424, "range80": { "low": 56946274215.3544, "high": 67896264844.90674, "baseline": 64315631983.66399, "n": 1471, "band": "b10", "bandLabel": "$10B+", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.06265007092149599, "classVolatility": 0.06659579566308972, "volatility": 0.06465304086610496 }, "ifPaceHeld": { "low": 56946274215.3544, "high": 67896264844.90674 } }, "edgarette": "🔖 Exposure: revenue $61.2B (FY2025), total debt $65.0B. Experience: revenue up 8.6% on the year, up 2.1% a year over 4 years; operating margin 24.6%, up from 16.2%. Soundness: equity -2.4% of assets (liabilities exceed assets), payout 275.4% of profit, dividend per share up 11 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $56.9B and $67.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $52.7B to $72.9B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 24.6% against a -3.8% median; growth 8.6% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "AbbVie (ABBV) grew revenue 8.6% in FY2025 to $61.2 billion, operating margin 24.6% against a -3.8% median for pharmaceutical preparations, equity -2.4% of assets, and dividend per share up 11 years running. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
AbbVie Inc. against its own record and its peers
Operating marginPeer median -3.8%24.6%Revenue, on the yearPeer median 13.7%8.6%Equity of assetsPeer median 40.3%-2.4%Payout of profitPeer median 40.3%275.4%Gold tick: the median of 13–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": "
Handed back now, or kept to compound
Of each dollar of profit120.0% paid outMore was paid out than was earned in the year.Handed back per share$6.65up 11 years runningRevenue growth it managed8.6%last year, for comparison

Gold is paid out to shareholders; navy is kept in the business. Retained profit times return on equity is the pace a company can fund from itself. Facts from the filings, not a recommendation.

", "backtest": { "tests": 11, "hits": 4, "rate": 0.36363636363636365, "method": "v4", "byYear": { "2015": [ 0, 1 ], "2016": [ 1, 1 ], "2017": [ 1, 1 ], "2018": [ 0, 1 ], "2019": [ 0, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 0, 1 ], "2023": [ 0, 1 ], "2024": [ 1, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-26T15:56:47.518Z", "hash": "417b922c414f69c6", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "AbbVie (ABBV) grew revenue 8.6% in FY2025 to $61.2 billion, operating margin 24.6% against a -3.8% median for pharmaceutical preparations, equity -2.4% of assets, and dividend per share up 11 years running. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 61160000000, "totalDebt": 64997000000, "cash": 5229000000 }, "experience": { "revenueGrowth1y": 0.08566762523520421, "revenueGrowthPerYear": 0.02138290840395274, "operatingMargin": 0.24648463047743624, "operatingMarginPrior": 0.16219334682429792, "netMargin": 0.06921190320470896, "freeCashFlow": 17816000000 }, "soundness": { "equityRatio": -0.02441027172290236, "returnOnEquity": null, "payoutRatio": 2.753838884951571, "dividendPerShare": 6.65, "dividendYearsRising": 11, "dividendCut": false, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-09-26", "signals": [], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 56946274215.3544, "high": 67896264844.90674, "baseline": 64315631983.66399, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 1471, "sizeBand": "$10B+", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.06265007092149599, "classVolatility": 0.06659579566308972, "pricedVolatility": 0.06465304086610496, "k": 3 }, "stress": { "low": 52712347760.81216, "high": 72853866431.06592, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 11, "hits": 4, "rate": 0.36363636363636365, "method": "v4", "byYear": { "2015": [ 0, 1 ], "2016": [ 1, 1 ], "2017": [ 1, 1 ], "2018": [ 0, 1 ], "2019": [ 0, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 0, 1 ], "2023": [ 0, 1 ], "2024": [ 1, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-26T15:56:47.518Z", "hash": "417b922c414f69c6", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001551152.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1551152" }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.3112, "growth3y": 0.0175, "volatility": 0.0627, "paysDividend": true, "raisedDividend": true, "equityRatio": -0.0244, "quadrant": { "code": "ss", "label": "Slow and steady", "plain": "growing slower than its size class, with steadier revenue" }, "compass": { "code": "steady", "inside": "Turns 31.1% of revenue into operating cash; revenue growing 1.8% a year over three years; pays and raised its dividend; liabilities exceed assets.", "outside": "Among $10B+ companies: 84th percentile for cash, 35th for growth.", "emoji": "🐂", "label": "Steady earner", "plain": "steady and paying a dividend, with average cash" }, "band": "$10B+", "cashPctInClass": 84, "growthPctInClass": 35, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "balance", "text": "liabilities exceed assets (often from years of share buybacks, not always distress)" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 19030000000, "investing": -6643000000, "financing": -12724000000, "capitalSpending": 1214000000, "free": 17816000000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": 22777000000, "free": 21990000000 }, { "fiscalYearEnd": "2022-12-31", "operating": 24943000000, "free": 24248000000 }, { "fiscalYearEnd": "2023-12-31", "operating": 22839000000, "free": 22062000000 }, { "fiscalYearEnd": "2024-12-31", "operating": 18806000000, "free": 17832000000 }, { "fiscalYearEnd": "2025-12-31", "operating": 19030000000, "free": 17816000000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 5229000000, "shortTerm": 28000000, "longTerm": 268000000, "equityHoldings": null, "totalAssets": 133960000000, "ladder": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.3112, "growth3y": 0.0175, "volatility": 0.0627, "paysDividend": true, "raisedDividend": true, "equityRatio": -0.0244, "quadrant": { "code": "ss", "label": "Slow and steady", "plain": "growing slower than its size class, with steadier revenue" }, "compass": { "code": "steady", "inside": "Turns 31.1% of revenue into operating cash; revenue growing 1.8% a year over three years; pays and raised its dividend; liabilities exceed assets.", "outside": "Among $10B+ companies: 84th percentile for cash, 35th for growth.", "emoji": "🐂", "label": "Steady earner", "plain": "steady and paying a dividend, with average cash" }, "band": "$10B+", "cashPctInClass": 84, "growthPctInClass": 35, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "balance", "text": "liabilities exceed assets (often from years of share buybacks, not always distress)" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 19030000000, "investing": -6643000000, "financing": -12724000000, "capitalSpending": 1214000000, "free": 17816000000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": 22777000000, "free": 21990000000 }, { "fiscalYearEnd": "2022-12-31", "operating": 24943000000, "free": 24248000000 }, { "fiscalYearEnd": "2023-12-31", "operating": 22839000000, "free": 22062000000 }, { "fiscalYearEnd": "2024-12-31", "operating": 18806000000, "free": 17832000000 }, { "fiscalYearEnd": "2025-12-31", "operating": 19030000000, "free": 17816000000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 5229000000, "shortTerm": 28000000, "longTerm": 268000000, "equityHoldings": null, "totalAssets": 133960000000, "ladder": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }